Please login to the form below

Not currently logged in
Email:
Password:

vitamin D

This page shows the latest vitamin D news and features for those working in and with pharma, biotech and healthcare.

Shire finally bags EU approval for rare disease drug Natpar

Shire finally bags EU approval for rare disease drug Natpar

Shire's drug should only be used for patients who cannot be adequately controlled with standard therapy with calcium and vitamin D supplementation alone according to the EMA. ... and active vitamin D supplemental doses.

Latest news

  • J&J gets CHMP backing for broader Darzalex use J&J gets CHMP backing for broader Darzalex use

    ahead for Natpara (parathyroid hormone), a treatment for patients with chronic hypoparathyroidism who cannot be adequately controlled with standard treatment with calcium and vitamin D.

  • A frugal future A frugal future

    Professor Brian D Smith is an authority on the pharmaceutical industry and works at SDA Bocconi University and Hertfordshire Business School. ... Or, in Homo sapiens, the evolution of pale skin as we moved out of Africa into higher latitudes with less

  • Relief for Shire as FDA clears NPS' Natpara Relief for Shire as FDA clears NPS' Natpara

    The US drugs regulator approved Natpara (recombinant parathyroid hormone) to treat low blood calcium levels - alongside calcium and vitamin D supplementation - in patients with the rare endocrine disease, which is caused ... This product offers an

  • Shire signs deal to buy NPS for $5.2bn Shire signs deal to buy NPS for $5.2bn

    If approved, Natpara would be the only bioengineered hormone replacement therapy indicated for the use of HPT, which is currently managed - often ineffectively - using high-dose oral calcium and vitamin D

  • Modern values in healthcare Modern values in healthcare

    Like dark skinned early humans who found themselves in higher latitudes with insufficient sunlight to create vitamin D, pharma companies find themselves faced with needing to develop new genes (i.e. ... Professor Brian D Smith.

More from news
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    The relentless commitment to deals reflects the fall from grace of investment for in-house R&D. ... The presence of the CRL on the books however did not deter Vifor Fresenius Medical Care Renal Pharma's decision to license Rayaldee [a vitamin D

  • Deal Watch February 2016 Deal Watch February 2016

    Another route to divestment is to out-license drug candidates to new companies that can dedicate R&D resources to progress the development of those assets. ... investment. 42.5. ††† Rockwell Medical Technologies/ Wanbang Biopharmaceuticals. Triferic

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • The vitamin D deficiency: should we act?

    So we’ re all at-risk of a vitamin D deficiency – but will we alter our lifestyles accordingly? ... It is presumed these delays were due to the huge wealth of ever-growing information regarding vitamin D.

  • When is sun safety doing more harm than good?

    We get most of our vitamin D from sunlight on our skin, and last year guidance from the  National Institute for Health and care Excellence (NICE) said that  one in five ... Britons may now be deficient in vitamin D.

  • Say Communications

    The vitamin D deficiency: should we act?. ... Healthcare PR agency Say Communications analyses whether headlines are able to trigger a behavioural change with regards to the vitamin D deficiency issue.

  • Four Health Communications

    Fractyl; medical technology. Internis (UK); vitamin D. SEEK; biotechnology . Nordic Pharma; antibiotics, rheumatology.

More from PMHub
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics